Dent disease is a pathology that affects various renal functions and is considered a rare disease for which, there is no effective treatment. To raise conscience and awareness of society, and help other families in the same situation, Eva Giménez - mother of Nacho Muñoz - founded ASDENT (Dent Disease Association). The association has the aim of raising funds to help the biomedical research of Dent disease and save the life of her son, as well as, of other patients with same pathology. The Vall d'Hebron Institute of Research (VHIR) and the biotechnology company Nostrum Biodiscovery (NBD) are working on a new project that aims to take a step towards the generation of a drug that will help treat Nacho.One of the main drivers of this alliance has been the Vall d'Hebron Research Institute, which has been leading the investigation of the disease for years, with the participation of Dr. Anna Meseguer, head of the research group in Physiopathology Renal - CIBBIM - Nanomedicine of VHIR and Dr. Gema Ariceta, principal investigator of the same group, head of the Pediatric Nephrology Service of Vall d'Hebron and doctor of Nacho. Throughout the treatment of Nacho during these 8 years, the solidarity of the ASDENT partners - anonymous and voluntary persons - have managed to contribute the amount of euros 500,000 to the two reference hospitals in research for this disease - Vall d'Hebron and La Candelaria - thus achieving important results towards the possible treatment of this pathology.The union of years of work dedicated to the investigation of the disease of Dent together with the company NBD - specialized in the acceleration of the development of drugs based on supercomputing technology - have resulted in the creation of this initiative of solidary collaboration, which It seeks to take a step forward on the path to the cure of Nachos' pathology. NBD I Nostrum Biodiscovery has considered the project as a great opportunity to bring biotechnology to people and thus achieve tangible results for an incurable disease, which given its minority characteristic is outside of the large pharmaceutical investments made by leading companies in the sector. Eva Giménez, is now in another of its major challenges to fund this project with the help of new donations from private companies and anonymous individuals committed to the cause.This is an agreement of shared values by all involved, which is being done with great enthusiasms. It reminds us that many of the rare diseases go unnoticed by the industry. Thanks to the collaboration of professionals, companies and committed institutions, research programs and possible treatments can be made possible. Otherwise would not be possible.